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AValue-based health care is increasingly promoted as a strategy for improving care quality by
benchmarking outcomes that matter to patients relative to the cost of obtaining those outcomes. To
support the shift toward value-based health care in chronic kidney disease (CKD), the International
Consortium for Health Outcomes Measurement (ICHOM) assembled an international working group
of health professionals and patient representatives to develop a standardized minimum set of patient-
centered outcomes targeted for clinical use. The considered outcomes and patient-reported
outcome measures were generated from systematic literature reviews. Feedback was sought from
patients and health professionals. Patients with very high-risk CKD (stages G3a/A3 and G3b/A2-G5,
including dialysis, kidney transplantation, and conservative care) were selected as the target pop-
ulation. Using an online modiﬁed Delphi process, outcomes important to all patients were selected,
such as survival and hospitalization, and to treatment-speciﬁc subgroups, such as vascular access
survival and kidney allograft survival. Patient-reported outcome measures were included to capture
domains of health-related quality of life, which were rated as the most important outcomes by
patients. Demographic and clinical variables were identiﬁed to be used as case-mix adjusters. Use of
these consensus recommendations could enable institutions to monitor, compare, and improve the
quality of their CKD care.Introduction
Chronic kidney disease (CKD) is an increasingly prevalent
clinical and public health problem worldwide, affecting
about 8% to 16% of the general population.1,2 CKD is
associated with adverse health outcomes, poor health-
related quality of life (HRQoL), and high health care
costs3-5 and contributes substantially to the negative
impact of the 4 main noncommunicable diseases identified
by the World Health Organization (cardiovascular diseases,
cancers, chronic respiratory diseases, and diabetes).1,3,4
CKD care aims to preserve or restore HRQoL, maintain
kidney function and prevent or delay progression to
advanced CKD, prevent and manage complications, and, in
advanced CKD, manage uremia through hemodialysis
(HD), peritoneal dialysis (PD), kidney transplantation,
or conservative care (ie, care for patients who, after pre-
dialysis counselling, choose not to undergo kidney
replacement therapy, as recently defined by KDIGO [Kid-
ney Disease: Improving Global Outcomes]6). However,
significant variation exists in CKD care and treatment
practices between institutions and countries.2,3,7-9
Value-based health care and shared decision making are
increasingly being promoted as a strategy for improving
care quality. Based on the principles formulated by Porter
and Teisberg,10,11 value is defined as health outcomes
achieved per monetary unit spent: value = outcomes/cost.JKD Vol XX | Iss XX | Month 2018Shared decision making requires that essential information
on patient-relevant outcomes is discussed among the
patient and health care professionals so that a given
approach to disease will yield a solution aligning as much
as possible with the patient’s values and preferences. For
both value-based health care and shared decision making,
defining the outcomes that matter to patients and other
stakeholders so they can be collected in a standardized way
is the first step.12
Although efforts to report outcomes of routine CKD
care exist, for example, well-established registries13 or
multinational cohort studies such as the Dialysis Outcomes
and Practice Patterns Study (DOPPS),14 there is no inter-
nationally accepted standardized approach to report out-
comes of CKD care. Moreover, although survival outcomes
and biochemical markers are frequently collected, patients’
reports of their HRQoL are still rarely recorded routinely
despite increasing recognition of their importance.15-19
This lack of an agreed standardized approach hinders
routine monitoring and benchmarking of different indi-
vidual clinical practices. To help improve CKD care and
shared decision making would require having identical,
meaningful, and patient-relevant outcomes of care recor-
ded in routine clinical practice. Furthermore, true
comparison would only be possible when correction for
case-mix is reliably achieved.1
Special ReportFor research, the need for standardization of outcome
measurement in CKD was previously recognized by the
Standardised Outcomes in Nephrology (SONG) initia-
tive.20-23 To support the development of a standardized
outcome set in CKD for integration into routine clinical
practice, the International Consortium for Health
Outcomes Measurement (ICHOM; www.ichom.org)
convened an international multidisciplinary working
group of experts and patient representatives. The aim of
the project was to propose a standardized minimum
set of patient-centered outcomes for CKD, including
patient-reported outcome measures (PROMs) and case-
mix factors to increase the usefulness of comparisons
across treatment modalities and institutions, targeted
for clinical use to enable standardization of health
outcome measurement in routine clinical practice in
different settings.Approach
Composition of Working Group
ICHOM, as a not-for-profit activity, has previously
developed standardized sets of value-based outcomes for
use in routine clinical practice in various medical con-
ditions, such as coronary artery disease,24 stroke,25 and
cancer (including breast,26 colorectal,27 and prostate
cancer28). To develop a standardized minimum set of
health outcome measures for CKD, ICHOM aimed to
establish a geographically diverse expert group that
covered a broad range of specialties in CKD. The working
group started with 22 members, including cliniciansFigure 1. Summary of the development of the chronic kidney dise
2(nephrologists and transplantation surgeon), CKD regis-
try experts, epidemiologists, kidney care providers,
research scientists, and 2 patient representatives, from 9
countries in Europe, North America, Latin America, the
Middle East, and Asia. Five members left the working
group. A project team (W.R.V., Z.D.-G., C.R., M.J.S., and
W.J.W.B.) guided the efforts of the working group.
Development of the CKD Standard Set
The working group convened using 8 teleconferences
between September 2016 and September 2017,
following a structured process similar to that of previous
ICHOM working groups (Fig 1).24-28 In brief, the
development of the standard set involved several phases:
defining scope; prioritizing and defining outcome do-
mains; selecting outcome measures, including clinical
data and PROMs; prioritizing and defining case-mix
domains; and selecting case-mix measures. Before each
teleconference, the project team summarized relevant
evidence from the literature and registries and inter-
viewed individual working group members with exper-
tise on specific topics to generate a list of items for
discussion. These documents were shared with the
working group in advance of each call.
Identiﬁcation of Potential Outcomes and Case-Mix
Variables
The project team performed a systematic literature review,
following PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-analyses) guidelines,29 ofase standard set.
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Special ReportPubMed-indexed articles published January 1, 2005, to
September 19, 2016, to identify potential outcome
domains, PROMs, and case-mix variables (Item S1). This
search retrieved 2,566 articles, of which 1,043 were
included for review.
We also reviewed registries of dialysis and kidney
transplantation patients for outcome measurement and
case-mix adjustment. Registries were identified from a
systematic review by Liu et al,13 by searching links on
registry websites, and by internet searches (Item S2). To
increase patients’ input in identifying potential outcome
domains, 5 patients with CKD participated as a patient
advisory group in a breakout session using teleconfer-
encing in October 2016 to explore their perspectives on
the importance of different outcomes and what affected
patients most during their day-to-day activities. We per-
formed an additional literature review to identify studies of
patients’ perspectives on the most relevant outcome
domains in CKD. This search retrieved 1,250 articles, of
which 6 were included for review (Item S1).
Consensus Process
Following each teleconference, the project team circulated
detailed minutes and an electronic survey to the working
group to vote and gather feedback on each key decision
point. We used an online 2-round modified Delphi pro-
cess, following RAND/University of California at Los
Angeles methodology30 and based on literature review,31
to achieve consensus on which outcomes and case-mix
variables should be included (Tables S1 and S2). Inclu-
sion in the standard set required that at least 70% of the
working group voted an item as very important (score of
7-9 on a 9-point Likert scale) in either voting round. We
used a similar process to agree on which outcome and
case-mix measures and PROM tools should be recom-
mended. Results of each vote were reviewed by the
working group at the next teleconference. When
consensus was not reached by voting, the topic was
rediscussed at the following teleconference. The criteria by
which we assessed outcome domains for inclusion in
the set were: (1) frequency of the outcome, (2) impact
on the patient, (3) potential for modifying the outcome,
and (4) feasibility of measuring the outcome. Variables to
be used as case-mix adjusters were assessed on: (1)
relevance, (2) independency, and (3) the feasibility of
measurement.
Selection of PROMs
After the outcomes had been chosen for inclusion in the
standard set, we identified the corresponding PROMs
from the literature and registry review.32-37 In targeted
searches, the original and validation studies of the in-
struments were retrieved. We systematically evaluated
PROMs for psychometric quality, domain coverage, and
feasibility of measurement and implementation using the
International Society for Quality of Life Research criteria
(Table S3).38AJKD Vol XX | Iss XX | Month 2018Patients’ Review of Outcomes
Patients with CKD (n = 358), recruited via national and
international patient organizations (Item S3), reviewed
the proposed list of outcomes. Participants were asked to
complete an anonymized online survey, available in En-
glish, Spanish, and Dutch, rating the importance of each
proposed outcome on a 9-point Likert scale and indi-
cating whether the list captured the most important
outcomes, including the option to suggest additional
outcomes in free-text form. The project team performed
a qualitative analysis on the free-text responses to identify
outcomes missing in the proposed list. The working
group discussed all findings and voted on the next steps.
External Input
Health professionals and other interested stakeholders in
outcome measurement (n = 70), recruited via profes-
sional associations (Item S3), reviewed the final draft of
the standard set and provided feedback using an online
English-language survey. They were asked to rate their
confidence regarding several elements of the set (eg,
completeness and implementation feasibility) on a 9-
point Likert scale, with an open field for comments.
The working group discussed the findings and voted on
the next steps.Findings
Scope
The working group selected adult patients (aged ≥18
years) with a diagnosis of very high-risk CKD, corre-
sponding to KDIGO classification stages G3a/A3 and G3b/
A2 to G5, regardless of underlying cause (Fig 2),39 as the
population of interest for the standard set. Treatment
modalities that were included were management of
pre–end-stage kidney disease (pre-ESKD; defined here as
stages of CKD prior to kidney failure, whether or not
kidney replacement therapy is planned), HD, PD, kidney
transplantation, and conservative care. Patients with acute
kidney injury, except those who progressed to very high-
risk CKD after 3 months, were not included in the scope of
this project because the disease course and care goals are
different for acute kidney injury and CKD.
Outcomes
We identified a total of 76 outcome domains from a sys-
tematic literature review, assessment of registries, and
input from the patient advisory group (Table S1). After a
consensus vote, 19 outcome domains were included in the
standard set (Table 1): 9 relevant to all patients with CKD,
and 10 to treatment-specific subgroups. We categorized
these outcome domains into 4 groups: (1) patient survival,
(2) burden of disease (eg, hospitalization rates and com-
plications), (3) patient-reported outcomes on HRQoL, and
(4) treatment modality–specific outcomes. We pragmati-
cally determined recommended measurement time points3
Figure 2. Scope for the chronic kidney disease (CKD) standard set was deﬁned as adult patients (aged ≥18 years) diagnosed with
very high-risk CKD, corresponding with KDIGO (Kidney Disease: Improving Global Outcomes) classiﬁcation stages G3a/A3 and
G3b/A2 to G5, regardless of underlying cause. Abbreviation: GFR, glomerular ﬁltration rate. Heat map is copyright 2012 KDIGO;
reproduced from the CKD guideline39 with permission of KDIGO.
Special Reportof the included outcomes, balancing between meaningful
time points when outcomes may be expected to change
and the feasibility of data collection (Table 1; Fig 3).
Patient Survival
We selected patient survival (determined by assessing
overall survival time and cause of death) for inclusion.
Identified problems in collecting data for cause of death
included the validity of such data and the practical impli-
cations of detailed data collection, but we believed
that cause of death is a key factor in understanding long-
term outcomes of CKD care. We recommend use of
a simplified version of the coding standard for causes
of death from the ERA-EDTA (European Renal
Association–European Dialysis and Transplant Association)
Registry, which was developed by the Scottish Renal
Registry.40
Burden of Disease
Hospitalization and cardiovascular events were selected as
measures of burden of disease. We decided to define
hospitalization as the number of admissions and of days
spent in hospital, rather than by collecting dates of each4admission and discharge. Dialysis-free time was considered
as an additional outcome relevant to HD patients, but we
noted that not all health services are able to provide
frequent dialysis, so dialysis-free time may not be an
accurate representation of better health. Cardiovascular
events of interest included acute myocardial infarction,
stroke, and limb amputation. We decided not to include
side effects of medication, primarily because side effects
are specific to different drugs and lack standardized
assessments.
Patient-Reported Outcomes for HRQoL
The working group prioritized 6 patient-reported outcome
domains for HRQoL: general HRQoL, pain, fatigue,
physical function, depression, and daily activity (Table 1).
The final voting result on depression was inconclusive, but
we decided to include depression because it was given a
high rating of importance by the patient representatives
(Table S1). Our aim was to select a PROM with good
psychometric performance that would capture all 6
outcome domains for HRQoL and provide scores for each
individual domain while minimizing respondent and
administrative burden. Of 41 PROMs identified,32-36 theAJKD Vol XX | Iss XX | Month 2018
Table 1. Summary of Outcomes for the CKD Standard Set
Patient Population Measure Details Timing Data Source
Survival
All pts Survival Date and cause of death Ongoing Clinical or
administrative data
Burden of Disease
All pts Hospitalization No. of admissions, days in hospital Annually Administrative data
CV events AMI, stroke,a limb amputationb Annually Clinical or
administrative data
Patient-Reported Outcomes for HRQoL
All pts HRQoL Tracked with SF-36, RAND-36, or
PROMIS Global Health +
PROMIS-29
6-monthly: HD, PD, & conservative care pts;
Annually: pre-ESKD & KT pts
Patient reported
Pain
Fatigue
Physical function
Depression
Daily activity
Treatment Modality–Speciﬁc Outcomes
Pre-ESKD & conservative
care pts
Kidney function eGFRc and/or Scr 6-monthly Administrative data
Pre-ESKD, KT, & conservative
care pts
Albuminuria UACR or UPCR in spot urine Annually Administrative data
HD, PD, & KT pts Bacteremia Positive blood culture with clinical signs 6-monthly Clinical data
HD pts Vascular access survival Tracked with status of vascular access 6-monthly Clinical or
administrative data
PD pts PD modality survival Tracked with status of PD modality Annually Clinical or
administrative data
Peritonitis Clinically suspected and/or culture proven 6-monthly Clinical data
KT pts Kidney allograft function eGFRc and/or Scr 6-monthly Administrative data
Kidney allograft survival Tracked with status of transplant Annually Clinical or
administrative data
Acute rejection Clinically suspected and/or biopsy-provend 6-monthly in ﬁrst year, then annually Clinical data
Malignancies Solid tumor, skin cancer, & hematologic
malignancies
Annually Clinical or
administrative data
Note: A detailed deﬁnition of each outcome can be found in the online reference guide (freely available at www.ichom.org/medical-conditions/chronic-kidney-disease/).
Abbreviations: AMI, acute myocardial infarction; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CV, cardiovascular; eGFR, estimated glomerular ﬁltration rate, HD, hemodialysis; KT, kidney transplantation; PD,
peritoneal dialysis; PROMIS, Patient-Reported Outcomes Measurement Information System; HRQoL, health-related quality of life; Scr, serum creatinine; SF-36, 36-Item Short Form Health Survey; UACR, urinary albumin-creatinine
ratio; UPCR, urinary protein-creatinine ratio.
aExcluding transient ischemic attack.
bLimb amputation not due to traumatic injury.
ceGFR calculated using the CKD-EPI creatinine equation (preferred) or other equations.
dBiopsy-proven acute rejection according to Banff classiﬁcation category 2, 3, or 4.50
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Figure 3. Algorithm for measurement time points of the chronic kidney disease (CKD) standard set. Abbreviations: ESKD, end-stage
kidney disease (ie, non–kidney failure CKD); KRT, kidney replacement therapy.
Special Report16 most commonly used PROMs were reviewed
(Table S3), discussed by the working group, and voted on.
We recognized that a generic PROM could be used to
measure all 6 HRQoL domains rather than one specific to
CKD or a particular treatment. A major advantage of a
generic PROM is that such tool could be used across
treatment modalities and across other diseases, which is
relevant in the CKD population, and recommended for
multimorbid patients.41
Despite extensive evaluation and discussion, the work-
ing group did not reach consensus on a single preferred
instrument because each PROM was believed to have its
own merits and limitations, so 3 tools were recom-
mended: the 36-Item Short Form Health Survey (SF-36)
version 2,42 RAND-36,43 and the combination of the
Patient-Reported Outcomes Measurement Information
System (PROMIS)-Global Health and PROMIS-29.44 The
SF-36 is widely used and well validated, but its use re-
quires a license fee.32-36 RAND-36 is an older version of
the SF-36 without a license fee, but is only available in
English and Arabic. The 2 PROMIS tools are both short
forms based on extensive item banks, are available in paper
and electronic versions, and have been validated in general
populations.45,46 CKD validation studies are currently be-
ing performed.47 The disease-specific Kidney Disease
Quality of Life (KDQOL) measures were not preferred
because the KDQOL Short Form (KDQOL-SF) contains
substantially more questions than strictly needed to mea-
sure the 6 HRQoL domains, while the 36-Item KDQOL
(KDQOL-36) provides only 2 summary scores on physical
and mental health. Each recommended PROM can be
completed in about 10 minutes and provides scores for all
6 outcome domains of interest and 2 overall scores of
physical and mental health. To enable comparisons among
the PROMs, most measures of the same outcome domain6can be translated into a common metric, developed by
PROsetta Stone (www.prosettastone.org). We decided that
it was most important to recommend use of a selection of
PROMs rather than 1 specific PROM; because the field is
rapidly changing, other PROMs may be considered in re-
visions of the standard set.
Treatment Modality–Speciﬁc Outcomes
Kidney function, or kidney allograft function, and albu-
minuria were included as measures of disease control for
patients with pre-ESKD CKD, conservative care patients,
and kidney transplantation patients. Recognizing that
measurement of these outcome domains varies across in-
stitutions (eg, use of different equations for estimated
glomerular filtration rate), we decided to include several
measurement methods and selected a preferred option for
comparison purposes, based on KDIGO guidelines39,48:
estimated glomerular filtration rate calculated using the
CKD-EPI (CKD Epidemiology Collaboration) creatinine
equation for kidney/kidney allograft function and
urinary albumin-creatinine ratio in spot urine specimens
for albuminuria. Because different laboratories use
different measurement techniques, we recommend to
assess type of serum creatinine and albuminuria assay and
whether isotope-dilution mass spectrometry calibration
standardization is used.49
We considered infections as an important outcome
domain in all patients undergoing kidney replacement
therapy. Due to lack of standardized assessments, the
domains for assessment of these outcomes were restricted
to bacteremia in HD, PD, and kidney transplantation
patients (positive blood culture with clinical signs,
excluding contamination) and peritonitis in PD patients
(clinically suspected and/or culture-proven infection). We
also included outcomes of treatment modality survival: PDAJKD Vol XX | Iss XX | Month 2018
Table 2. Summary of Case-Mix Variables for the CKD Standard
Set
Patient Population Measure
Data
Source
Demographic Factors
All pts Age Patient
reportedSex
Education levela
Baseline Clinical Factors
All pts Comorbid conditionsb Clinical
abstractionSmoking status
Body mass index
Primary kidney
diseasec
Pre-ESKD &
conservative care pts
Baseline kidney
function
Pre-ESKD, KT, &
conservative care pts
Baseline albuminuria
HD, PD, KT, &
conservative care pts
Previous treatments
HD pts Vascular acces typed
KT pts Baseline kidney
allograft function
KT pts Transplant typee
Note: A detailed deﬁnition of each case-mix variable can be found in the online
reference guide (free available at www.ichom.org/medical-conditions/chronic-
kidney-disease/).
Abbreviations: CKD, chronic kidney disease; ERA-EDTA, European Renal
Association–European Dialysis and Transplant Association; HD, hemodialysis; KT,
kidney transplantation; PD, peritoneal dialysis; pt, patient.
aEducation level deﬁned as highest attained education. Level of schooling deﬁned
in each country according to the International Standard Classiﬁcation of Education.
bComorbid conditions include hypertension or use of antihypertensive medication,
diabetes mellitus, chronic lung disease, chronic liver disease, cardiovascular
events, and malignancies.
cPrimary kidney diseases according to categories based on simpliﬁed ERA-EDTA
coding system: uncertain cause, diabetes mellitus, glomerulonephritis, hyperten-
sion, polycystic kidney disease, pyelonephritis, kidney vascular disease, or other
(indicate).
dVascular access type includes arteriovenous ﬁstula, arteriovenous graft, and
catheter.
eTransplant from living or deceased donor.
Special Reportmodality survival in PD patients and kidney allograft sur-
vival in kidney transplantation patients. Vascular access
survival was voted to be a relevant outcome for HD pa-
tients. Surgical complications, such as complications after
vascular access surgery, PD catheter surgery, and kidney
transplantation, were not included in the final set because
of lack of standardized assessments of these complications.
Acute rejection of a kidney transplant (clinically suspected
and/or biopsy-proven acute rejection according to Banff
classification category 2, 3 and 450) and malignancies were
included as important measures of treatment complications
for kidney transplantation patients.
Case-Mix Variables
After voting (Table S2), we selected a minimum set of
case-mix variables to enable meaningful comparisons
across treatment modalities and institutions (Table 2).
Demographic factors included age, sex, and education
level. We selected education level (defined as the highest
level of schooling attained) as a surrogate for socioeconomic
status, being easily obtainable and internationally compara-
ble,51 in line with previous ICHOM work. The prohibition
against collecting data for race or ethnicity in several coun-
tries and the lack of an internationally standardized method
for collecting these data led to the decision to exclude race or
ethnicity as a case-mix factor from the current set.
Clinical factors included smoking status, nutritional
status by body mass index, comorbid conditions, primary
kidney disease, baseline kidney/kidney allograft function,
baseline albuminuria, and characteristics of previous and
current treatment modality. Comorbid conditions of in-
terest were based on the Charlson Comorbidity Index,52
Davies comorbidity score,53 and Khan index.54-57 Pri-
mary kidney diseases were based on a simplified version of
the ERA-EDTA coding system.58
Patients’ Review of Outcomes
Of the 358 patients who participated in the online review
survey between March and June 2017, a total of 75%
(270) believed that the proposed list of outcomes captured
the most important outcomes. Patients ranked the HRQoL
domains as most relevant (Fig 4); 115 respondents pro-
vided free-text responses, in which health literacy and
ability to work were the most frequently raised additional
outcomes (Table S4). However, we could not find vali-
dated or freely available measurement tools for these
outcome domains and recommend developing such tools
as a research priority. If such tools become available, health
literacy and work ability should be reconsidered for in-
clusion in the standard set.
Stakeholder Consultation
The health professionals and care providers (n = 70) who
completed the online survey on the proposed standard set
were confident that the set represented a comprehensive
view of the most essential outcomes for patients with CKD
and about the feasibility of data collection in routineAJKD Vol XX | Iss XX | Month 2018clinical practice (Table S5; mean score, 6.9 on a 9-point
Likert-type scale). Their main concerns were related to
challenges around implementation of the standard set,
availability of data, and the number of measures included
in the set (see next section).
Data Collection and Implementation
Concerned about the standard set’s length and potential
difficulties in implementation, we reconsidered the out-
comes included in the set and decided to group the out-
comes into 2 tiers: an essential tier, which includes the
PROMs, and an important tier (Fig 5). Health care pro-
viders implementing the set should focus on monitoring
outcomes in the essential tier and include the important
tier if feasible.
A reference guide is freely available on ICHOM’s
website (www.ichom.org/medical-conditions/chronic-
kidney-disease/), including a data dictionary for all vari-
ables, potential data sources, and recommended timelines
for data collection.7
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Figure 4. Results of the online review survey among patients with chronic kidney disease (n = 358) on the proposed outcomes. The
survey included all outcomes with supporting deﬁnitions. Respondents had to rate the importance of each outcome on a 9-point
Likert scale (7-9, “essential”; 4-6, “important”; and 1-3, “not relevant”). The response option “unable to score” was included, for
example, for patients having no experience with speciﬁc treatment modalities (eg, hemodialysis, peritoneal dialysis [PD], or kidney
transplantation). Abbreviation: HRQoL, health-related quality of life.
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On the basis of patient input, literature reviews, assessment
of registries, and expert consensus, an international
multidisciplinary working group defined a minimum set
of patient-centered outcomes for CKD that should be
recorded in routine clinical practice to support the shift
toward value-based health care in CKD and improve shared
decision making. The working group focused on outcomes
relevant to patients with very high-risk CKD (stages G3a/
A3 and G3b/A2 to G5, including HD, PD, kidneySurvival
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specific subgroups. The set includes outcomes that are
important to patients but that are less routinely collected,
such as HRQoL, and a minimum of demographic and
clinical factors to be used for case-mix adjustment across
treatment modalities and institutions.
In nephrology, data collection of health outcomes in
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Special Reportprovided the foundation for quality improvement in CKD
care in many countries; for example, after observing dif-
ferences in health outcomes across different care set-
tings.8,59-61 However, comparisons and data sharing across
health systems have been restricted to the involved
institutions and countries and (in addition to mortality) to
intermediate and process outcomes of CKD care, such as
biochemical parameters, that are most easily accessible.15
Furthermore, most data collection has focused on patients
undergoing dialysis or kidney transplantation, which
misses opportunities to optimize care at an earlier stage to
prevent or delay CKD progression. Standardization of
outcome measurement in clinical practice based on out-
comes that matter to patients is needed as a first step to
enable benchmarking and quality improvement in CKD care
on a larger scale and improve shared decision making.62,63
Such standardization of outcomes was previously recog-
nized for research by the SONG initiative.20-23 Our work is
a multinational effort to recommend a standardized mini-
mum set of health outcome measures for use in routine
clinical practice across different settings worldwide, incor-
porating PROMs that are important to a broad spectrum of
patients with CKD, including those with pre-ESKD stages.
It is important to recognize that this standard set does
not include all outcomes that may matter to patients and
other stakeholders. Our aim was to define a minimum
standard set of health outcomes relevant to patients with
CKD while balancing the practicalities and burden of data
collection, finding the most appropriate PROMs and case-
mix variables, and recommending meaningful but feasible
measurement time points. Specific for the recommended
PROMs, the prioritization of the 6 HRQoL domains
and the subsequent assessment of domain coverage
per PROM substantially guided our selection. Generic
PROMs appeared to be the most appropriate, which is
somewhat contrary to existing recommendations for
HRQoL measurement in CKD that propose to combine
generic and kidney disease–targeted components.64-66
However, in such recommendations, domain coverage is
often missing as a selection criterion or is not needed due
to a difference in purpose. We encourage care providers to
measure additional outcome domains, use additional
PROMs (eg, more detailed symptom- or treatment-specific
instruments) or case-mix adjusters (eg, race/ethnicity),
and measure at more frequent time points to meet their
specific requirements.
As with any process of standard set development, there
are limitations to our approach. The current recommen-
dations reflect the opinion of a selected group of experts
and patient representatives. We informed our discussions
by evidence reviews and aimed to collect as much feedback
as possible from patients, health professionals, and other
relevant stakeholders. We sought to achieve a high level of
transparency by using a modified Delphi technique to
document our decision-making process. Feedback from
the online review surveys suggested that patients, health
professionals, and other stakeholders were confident thatAJKD Vol XX | Iss XX | Month 2018the standard set included the most important outcomes.
However, we were not able to include health literacy and
work ability, which had been identified as important
outcome domains in the online review survey of patients,
because of the lack of valid or freely available assessment
tools. Our results include some similar outcome domains
to those from the SONG initiative on defining core out-
comes for nephrology research67-69 and to results from
studies of patients’ outcome priorities.70-72 In the SONG
initiative, patients rated aspects of HRQoL as more
important than survival. Our patient reviewers rated
HRQoL as important as survival. We recommend that the
current set be used as a starting point for standardized
registration and collection of patient-centered outcomes in
CKD care. A steering committee, made up of a subgroup of
the working group including a patient representative, will
convene annually to review new evidence and expertise,
including new developments in the field of PROMs, and
continue to refine the standard set.
We recognize that implementation of the standard set in
routine clinical practice may be challenging in many settings
because it may require investment in resources for collection
of data (including PROMs) and infrastructure development
(including linkages with administrative data sources), as well
as alignment with existing registries and outcome mea-
surement efforts. Moreover, as patients wish to discuss in-
dividual outcomes and PROM results to guide their
treatment, which was explicitly expressed by the patient
representatives in our working group, new practice patterns
would need to be developed to do so.73,74 For these reasons,
we consider the standard set as a goal rather than a threshold.
We envision that implementation involves 4 phases: (1)
preparation, to engage clinical leaders and set up an
appropriate governance process; (2) diagnostic, to deter-
mine current measurement practices and gaps and develop
strategies for collecting clinical data and PROMs at suitable
time points, (3) roll-out, to use pilot sites to test strategies
including for data collection, and (4) measurement, to
determine how to relay the data back to the clinical teams
and patients (Fig S1). To facilitate implementation, we
divided the list of outcomes into an essential tier and an
important tier, stressing the need to focus on the PROMs,
and added references on barriers and facilitators of
implementing PROMs in clinical practice.64,66,75-77 The
near-term goal will be to partner with pilot institutions to
implement the set as a proof of concept, which has been
successfully applied for other standard sets.78-80 The
experience and lessons learned in this pilot testing will be
documented, and the steering committee will use feedback
from this phase to refine the CKD standard set and prepare
it for widespread implementation.
To conclude, we have developed a consensus recom-
mendation for a standardized minimum set of health
outcomes that are deemed most important to patients with
CKD targeted for integration into routine clinical practice.
Use of the standard set enables institutions to monitor,
compare, and improve the quality of their CKD care.9
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Figure S1: Phases involved in implementation of the CKD standard
set.
Item S1: Literature review to identify potential outcomes, PROMs,
and case-mix variables in CKD studies to be considered for inclusion
in the CKD standard set, and to identify studies studies determining
CKD patients’ perspectives on the most relevant outcomes in CKD.
Item S2: Registry review to identify potential outcomes, PROMs,
and case-mix variables in registries to be considered for inclusion in
the CKD standard set.
Item S3: List of patient and professional organizations involved in
recruitment of patients, health professionals, and other stakeholders
for participation in the online review surveys.
Table S1: Voting results of 2-round modiﬁed Delphi process by
working group on outcomes.
Table S2: Voting results of 2-round modiﬁed Delphi method by
working group on case-mix factors.
Table S3: Overview of the review on PROMs for the included
outcome domains, and overview of domain coverage of PROMs.
Table S4: Results of the qualitative analysis on free-text responses
about missing themes reported by CKD patients participating in the
online review survey.
Table S5: Results of online review survey on the proposed CKD
standard set by health professionals, care providers, and other
stakeholders interested in outcomes measurement.
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